AUCKLAND, NZ: Truscreen Group Limited (ASX:TRU) announced the appointment of Dr. Beata Edling as Chief Executive Officer.

Dr. Edling joined TruScreen Group in October 2020 as Medical Affairs and Market Access Lead and has developed an intimate knowledge of the TruScreen cervical cancer screening technology and business.

She led the medical affairs and market access of TruScreen Group into new markets in Eastern Europe and the Balkan nations and inaugurated TruScreen’s International Experts Group. Dr Edling has also worked closely with TruScreen’s major distributors in China and in Vietnam.

Chairman, Mr Tony Ho, said, “As the world and our global markets normalise economic activities after COVID, it is timely that TruScreen continues with commercialisation of our cervical cancer screening technology.

The appointment of Sydney based Dr. Beata Edling will provide a sharper focus to growing our business as border restrictions are removed from our markets. The past COVID years were devoted to preparing the Company for post COVID commercial activities. We expect China to lift border restrictions in the next few months.”

“I would like to thank Mrs Juliet Hull, our Non-Executive Director for stepping in to lead the Company as Interim CEO during the past 20 months during the COVID period. Under Mrs Hull’s leadership, much was achieved by TruScreen, including completion of the critical supplier contract with Zapco International and transitioning of the global regulatory MDD to MDR platform. Mrs Hull will resume her role as a Non-Executive Director of TruScreen.”

Dr. Beata Edling holds a MD from the Medical University, Gdansk, Poland, and has completed part 1 of her Fellowship with Royal College of Surgeons, Australia. Dr Edling completed her PhD at the University of New South Wales, Australia, has a MBA from Sydney’s Australian Graduate School of Management, and is a graduate member of the Australian Institute of Company Directors.

Dr. Edling is an experienced executive who previously led large and small Medical Affairs Teams and commercialised numerous medical products with global pharmaceutical companies, Sanofi-Aventis, Shire, Eli Lily and Amgen for Australia and New Zealand.

Dr. Beata Edling was previously a Non-Executive Director of ASX listed Noxopharm Limited. Dr. Edling is multi-lingual and speaks several European languages.